- Unprecedented support received from regional conference underwriters -
SEATTLE--(BUSINESS WIRE)-- Life Science Innovation Northwest 2011, the Pacific Northwest’s premier investor and strategic partner conference, today announced that more than 70 organizations will present; and strategic discussions on critical local, national and global healthcare issues will be featured in six plenary sessions. The conference is scheduled for March 2 and 3 at the Washington State Convention Center Seattle.
Presentations by a wide mix of organizations provide an opportunity for executives from development- to commercial-stage public and private companies, research institutes and leading global health organizations to showcase their technologies, business strategies and innovations to leading investors and strategic partners. The select slate of life sciences organizations include Advanced Medical Isotope Corporation, Allon Therapeutics, Bill & Melinda Gates Foundation, Calistoga Pharmaceuticals, CMC Biologics, Emergent BioSolutions, Home Dialysis Plus, Insilicos, Oregon Health & Science University (OHSU), Omeros, Pacific Northwest Diabetes Research Institute (PNDRI), Seattle Genetics, SIGA Technologies, SonoSite, T-Ray Science, University of Washington Center for Commercialization (UWC4C), VLST, and Washington State University Research Foundation (WSURF) to name a few. For more information on Life Science Innovation Northwest 2011 (LSINW 2011) program please visit www.washbio.org.
“With presenting companies from British Columbia, California, Montana, Oregon and Washington, and delegations from more than ten countries, this regional conference has truly gone global,” noted Chris E. Rivera, President, Washington Biotechnology & Biomedical Association (WBBA). “The unprecedented level of support from our underwriters including, K&L Gates, University of Washington, Fenwick & West LLP, SightLife, Wells Fargo Insurance Services, Edelman Seattle, Perkins Coie, and Praxair, combined with the expert panelists at this year’s conference makes this a not-to-be-missed event.”
- Keynote presentations by James C. Greenwood, President & CEO, Biotechnology Industry Organization (BIO) and G. Steven Burrill, CEO, Burrill & Company and co-host of LSINW.
- Six strategic panel presentations, including:
- Partnering to Drive Innovation. This discussion defines how partnering benefits product development and innovation and will be moderated by Doug Williams (Biogen Idec), joined by executives from Alder Biopharmaceuticals, Allen Institute for Brain Sciences, Bill and Melinda Gates Foundation, Bristol-Myers Squibb, Fred Hutchinson Cancer Research Center, and Merck Research Laboratories.
- Life Sciences in the Pacific Northwest: Creating the Future. will be moderated by Stephen Graham (Fenwick and West) and includes executives from Amgen, CMC Biologics, NovoNordisk, Philips Healthcare, and Seattle Genetics.
- Lessons Learned: How to Position your Company for Success. Seasoned industry executives share anecdotes, experiences and critical guidance to succeed in today’s environment. Michelle Burris (OncoGenex Pharmaceuticals) will moderate the panel, and includes panelists from Calistoga Pharmaceuticals, Cell Therapeutics, Immune Design, Integrated Diagnostics, and Mirador Biomedical.
- Global Solutions, Local Benefit. Learn how innovation designed to meet the needs of developing nations, provides local benefits. Panel will be moderated by John Gardner (Washington State University) and includes panelists from Cascade Design and Swedish Hospital amongst other leading experts on the topic.
- Social, Political and Legal Issues Relating to Intellectual Property Rights. This dynamic panel lends perspectives and counsel from Intellectual Ventures, K&L Gates, University of Illinois at Chicago College of Medicine and University of Alberta.
- Early Stage Capital. Experts discuss views on the promise and impact of early stage funding to drive and fuel innovation from public institutions, angel and venture capital sources, as well as industry strategic investors. This panel is moderated by Franklin Berger (FMB Research), with panelists from Life Sciences Discovery Fund, NEA, PhaseRx, University of Washington’s Center for Commercialization, and WINGs.
- Speed-Dating: This fast-paced, exciting session fosters introductions and conversations between emerging companies, innovators, entrepreneurs and investors to initiate and facilitate fund-raising activities.
- Poster Alley: Poster sessions will be held throughout the conference, providing researchers and emerging organizations the opportunity to share cutting edge innovation with investors, CEOs, and entrepreneurs.
There is still time to apply for speed-dating and the poster session. The deadline is February 7.
Register now to take advantage of advance registration rates available through February 25. Or take advantage of a 20% discount on registration if you plan to attend both the Life Science Innovation Northwest 2011 and BioPartnering North America™.
LSINW 2011 would not be possible without the support of our sponsors and partners Life Sciences British Columbia, Montana BioScience Alliance, and Oregon Bioscience Association. If you are interested in being a sponsor, please contact Stacie Byars at [email protected] or 206-732-6705.
About LSINW 2011
Life Science Innovation Northwest 2011 is presented by The Washington Biotechnology & Biomedical Association (WBBA) and Burrill & Company. For more information on the LSINW 2011 conference, please visit www.washbio.org.
The Washington Biotechnology & Biomedical Association (WBBA) is an independent, non-profit 501(c)(6) trade association serving the life sciences industry in the state of Washington. Our members include organizations engaged in, or supportive of, research, development and commercialization of life science technologies. Our mission is to translate innovation to realization: from breakthrough discoveries to better health solutions. Learn more about the WBBA at www.washbio.org.
About Burrill & Company
Burrill & Company has established unrivaled access and visibility in the life sciences industry. With more than $1 billion in assets under management, the firm’s businesses include venture capital, private equity, merchant banking and media. A unique combination of resources and capabilities enables the company to provide life sciences companies with capital, management expertise, insight, market intelligence and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe and Asia. (www.burrillandco.com).
The Washington Biotechnology & Biomedical Association (WBBA)
Stacie Byars, 206-732-6705
KEYWORDS: United States North America Washington
INDUSTRY KEYWORDS: Health Biotechnology Genetics